HYPERCALCIURIC NEPHROLITHIASIS TRIAL BETWEEN UROPHOS-K AND UROCIT-K

描述：（直接取自应用）吸收性高钙尿症是一种结石形成的疾病，高钙尿症被认为是由肠道钙吸收的初级增强引起的。吸收性高钙尿可能是异质起源，可大致分为维生素d依赖型和维生素d依赖型。因此，除了复发性肾结石外，吸收性高钙尿症尚不清楚，但我们已经暗示了骨化三醇过量分解代谢骨骼效应的潜在作用。因此，由于目前的长期治疗远不能令人满意，理想的治疗方法应该是持续纠正肠道吸收和肾脏排泄过多的钙，并避免骨质流失。这一需求导致了我们的假设，即一种特殊配方的正磷酸盐（缓释中性磷酸钾或UroPhos-K）可以纠正高钙尿症，防止复发性结石形成，并为由于吸收性高钙尿症引起的高钙尿肾病提供安全的使用。在一项对照随机试验中，将比较UroPhos-K与uroct - k（柠檬酸钾）在高钙血症合并吸收性高钙尿症患者中的作用。有待验证的假设是，与Urocit-K不同，UroPhos-K会降低尿钙，并且在抑制新结石形成方面比Urocit-K更有效。UroPhos-K在抑制新结石形成中的安全性和积极的物理化学和生理作用。从正在进行的长期非随机试验中披露的UroPhos-K的安全性和积极的物理化学和生理效应为启动该随机试验提供了动力。

Description: (Taken Directly from the application) Absorptive hypercalciuria is a stone-forming condition in which hypercalciuria is believed to result from the primary enhancement of intestinal calcium absorption. Absorptive hypercalciuria is probably heterogeneous in origin, and may be broadly categorized into vitamin D-independent and vitamin D-dependent forms. Thus, besides recurrent nephrolithiasis, absorptive hypercalciuria is not known, but we have implicated a potential role of the catabolic skeletal effect of calcitriol excess. Therefore, since current long-term treatment is far from satisfactory, an ideal treatment should be one which produces a sustained correction of excessive intestinal absorption and renal excretion of calcium, and averts bone loss. This need has led to our hypothesis that a special formulation of orthophosphate (slow-release neutral potassium phosphate or UroPhos-K) would correct hypercalciuria, prevent recurrent stone formation and provide safety of usage in hypercalciuric nephrolithiasis due to absorptive hypercalciuria. In a controlled randomized trial, the effect of UroPhos-K will be compared with that of Urocit-K (potassium citrate) in hypercalciuric patients with absorptive hypercalciuria. The hypothesis to be tested is that UroPhos-K would lower urinary calcium unlike Urocit-K, and would be more effective than Urocit-K in inhibiting new stone formation. The safety and positive physicochemical and physiological effects of UroPhos-K in inhibiting new stone formation. The safety and positive physicochemical and physiological effects of UroPhos-K disclosed from ongoing long-term non-randomized trial provided the impetus to initiate this randomized trial.